276 related articles for article (PubMed ID: 15170903)
41. Leflunomide-associated infections in rheumatoid arthritis.
Jenks KA; Stamp LK; O'Donnell JL; Savage RL; Chapman PT
J Rheumatol; 2007 Nov; 34(11):2201-3. PubMed ID: 17937473
[TBL] [Abstract][Full Text] [Related]
42. Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified?
Rajakulendran S; Gadsby K; Deighton C
Musculoskeletal Care; 2008 Dec; 6(4):233-45. PubMed ID: 18702106
[TBL] [Abstract][Full Text] [Related]
43. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study.
Karanikolas G; Charalambopoulos D; Vaiopoulos G; Andrianakos A; Rapti A; Karras D; Kaskani E; Sfikakis PP
Rheumatology (Oxford); 2008 Sep; 47(9):1384-8. PubMed ID: 18603660
[TBL] [Abstract][Full Text] [Related]
44. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis.
Farahani P; Levine M; Gaebel K; Thabane L
Can J Clin Pharmacol; 2005; 12(3):e254-63. PubMed ID: 16278497
[TBL] [Abstract][Full Text] [Related]
45. Rheumatoid arthritis treatment with weekly leflunomide: an open-label study.
Jaimes-Hernández J; Robles-San Román M; Suárez-Otero R; Dávalos-Zugasti ME; Arroyo-Borrego S
J Rheumatol; 2004 Feb; 31(2):235-7. PubMed ID: 14760790
[TBL] [Abstract][Full Text] [Related]
46. Lupus erythematosus with leflunomide: induction or reactivation?
Gensburger D; Kawashima M; Marotte H; Kanitakis J; Miossec P
Ann Rheum Dis; 2005 Jan; 64(1):153-5. PubMed ID: 15608317
[TBL] [Abstract][Full Text] [Related]
47. Physical function and health related quality of life: analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis.
Strand V; Scott DL; Emery P; Kalden JR; Smolen JS; Cannon GW; Tugwell P; Crawford B;
J Rheumatol; 2005 Apr; 32(4):590-601. PubMed ID: 15801012
[TBL] [Abstract][Full Text] [Related]
48. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
49. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden.
Kristensen LE; Saxne T; Geborek P
Arthritis Rheum; 2006 Feb; 54(2):600-6. PubMed ID: 16447237
[TBL] [Abstract][Full Text] [Related]
50. Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drug.
Wardwell NR; Miller R; Ware LB
Respirology; 2006 Sep; 11(5):663-5. PubMed ID: 16916345
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.
Kaltwasser JP; Nash P; Gladman D; Rosen CF; Behrens F; Jones P; Wollenhaupt J; Falk FG; Mease P;
Arthritis Rheum; 2004 Jun; 50(6):1939-50. PubMed ID: 15188371
[TBL] [Abstract][Full Text] [Related]
52. [Leflunomide--a new disease modifying anti-rheumatic agent].
Rødevand E; Kvien TK; Johnsen V
Tidsskr Nor Laegeforen; 2001 Nov; 121(27):3181-4. PubMed ID: 11876141
[TBL] [Abstract][Full Text] [Related]
53. Subtherapeutic dosing of methotrexate in rheumatoid arthritis trials.
Parker CT; Mewshaw E; Dennis GJ
J Am Osteopath Assoc; 2004 Jan; 104(1):7-8. PubMed ID: 14992316
[No Abstract] [Full Text] [Related]
54. Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation.
van Roon EN; Hoekstra M; Tobi H; Jansen TL; Bernelot Moens HJ; Brouwers JR; van de Laar MA
Br J Clin Pharmacol; 2005 Sep; 60(3):319-25. PubMed ID: 16120072
[TBL] [Abstract][Full Text] [Related]
55. The use of low-dose prednisone in the management of rheumatoid arthritis.
Lim SS; Conn DL
Bull Rheum Dis; 2001; 50(12):1-4. PubMed ID: 12386945
[TBL] [Abstract][Full Text] [Related]
56. [Acute interstitial pneumonia in patient with rheumatoid arthritis treated with leflunomide].
Siemion-Szcześniak I; Bartoszuk I; Bartosiewicz M; Jakubowska L; Wesołowski S; Kuś J
Pneumonol Alergol Pol; 2014; 82(6):568-75. PubMed ID: 25339568
[TBL] [Abstract][Full Text] [Related]
57. How and when should combination therapy be used? The role of an anchor drug.
Farr M; Bacon PA
Br J Rheumatol; 1995 Nov; 34 Suppl 2():100-3. PubMed ID: 8535639
[TBL] [Abstract][Full Text] [Related]
58. [Can a combination therapy with leflunomide be recommended for patients with active rheumatoid arthritis?].
Hamann F
Z Rheumatol; 2003 Apr; 62(2):204-5. PubMed ID: 12820624
[No Abstract] [Full Text] [Related]
59. Risk of hepatotoxicity with add-on leflunomide in rheumatoid arthritis patients.
Gupta R; Bhatia J; Gupta SK
Arzneimittelforschung; 2011; 61(5):312-6. PubMed ID: 21755815
[TBL] [Abstract][Full Text] [Related]
60. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment.
Alivernini S; Mazzotta D; Zoli A; Ferraccioli G
Drugs Aging; 2009; 26(5):395-402. PubMed ID: 19552491
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
